, Volume 8, Issue 4, pp 295–301 | Cite as

Effects of scopolamine and atropine and their quaternized salts on avoidance behavior in the monkey

  • G. K. Samuel
  • J. K. Kodama
  • J. H. Mennear
Short Communications


Rhesus monkeys received the tertiary and quaternary forms of scopolamine and atropine intravenously and were tested in one of three avoidance situations. On the basis of MEDs for disrupting the learned behavior, scopolamine was estimated to be 3–32-fold more potent than atropine and at least 10–316-fold more potent than methyl scopolamine, and atropine was at least 3–100-fold more potent than methyl atropine. The effects produced by the two congeners are interpreted as being centrally mediated and the difference in potency between them as reflecting the relative ease with which each penetrates the blood-brain barrier.


Methyl Atropine Rhesus Monkey Scopolamine Avoidance Behavior 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Antonsen, S., and G. H. Nielsen: A quaternary atropine derivative. Acta pharmacol. (Kbh.) 20, 357–366 (1963).Google Scholar
  2. Boren, J. J.: The effects of tertiary and quaternary forms of scopolamine upon fixed ratio and fixed interval behavior. Paper read at American Psychological Association, St. Louis (Sept. 1962).Google Scholar
  3. Brady, J. V.: Differential drug effects upon aversive and appetitive components of a behavioral repetoire. In P. B. Bradley, P. Deniker, and C. Radouco-Thomas (Eds.); Neuro-Psychopharmacology, Vol. I, pp. 275–281. New York: Elsevier 1959.Google Scholar
  4. Carlton, P. L.: Some behavioral effects of atropine and methyl atropine. Psychol. Rep. 10, 579–589 (1962).Google Scholar
  5. —: Cholinergic mechanisms in the control of behavior by the brain. Psychol. Rev. 70, 19–39 (1963).Google Scholar
  6. Graham, J. D., and S. Lazarus: The actions of methyl atropine nitrate (Eumydrin). J. Pharmacol. exp. Ther. 70, 165–170 (1940).Google Scholar
  7. Herrnstein, R. J.: Effects of scopolamine on a multiple schedule. J. exp. Anal. Behav. 1, 351–358 (1958).Google Scholar
  8. Herz, A.: Über die Wirkung von Scopolamin, Benactyzin und Atropin auf das reaktive Verhalten der Ratte. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 236, 110–112 (1959).Google Scholar
  9. Mennear, J. H., R. Clark, G. K. Samuel, M. H. Joffe, and J. K. Kodama: The comparative psychopharmacologic effects of scopolamine and atropine. Fed. Proc. 22, 567 (1963).Google Scholar
  10. Parkes, M. W.: An examination of central actions characteristic of scopolamine: Comparison of central and peripheral activity in scopolamine, atropine and some synthetic basic esters. Psychopharmacologia (Berl.) 7, 1–18 (1965).Google Scholar
  11. Paul-David, J., J. L. Riehl, and K. R. Unna: Quantification of effects of depressant drugs on EEG activation response. J. Pharmacol. exp. Ther. 129, 69–74 (1960).Google Scholar
  12. Pfeiffer, C. C., and E. H. Jenney: The inhibition of the conditioned response of the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann. N.Y. Acad. Sci. 66, 753–764 (1957).Google Scholar
  13. Sidman, M.: Avoidance conditioning with brief shock and no exteroceptive warning signal. Science 118, 157–158 (1953).Google Scholar
  14. Stone, G. C.: Effects of drugs on nondiscriminated avoidance behavior. Psychopharmacologia (Berl.) 6, 245–255 (1964).Google Scholar
  15. Whitehouse, J. M., A. J. Lloyd, and S. A. Fifer: Comparative effects of atropine and methyl atropine on maze acquisition and eating. J. comp. physiol. Psychol. 58, 475–476 (1964).Google Scholar

Copyright information

© Springer-Verlag 1965

Authors and Affiliations

  • G. K. Samuel
    • 1
  • J. K. Kodama
    • 1
    • 2
  • J. H. Mennear
    • 1
    • 2
  1. 1.Hazleton LaboratoriesFalls Church
  2. 2.Division of Shell Oil CompanyShell Development CompanyModesto

Personalised recommendations